Common questions about Луцентис (FAQ)
Q: Is Lucentis the same as Eylea, or are there differences?
Lucentis (ranibizumab) and other medicines in its class, like Eylea (aflibercept), work by targeting the vascular endothelial growth factor (VEGF) protein. Official product information describes Lucentis as an antibody Fab fragment, which is defined by its specific molecular size and structure. These structural characteristics are key points of comparison cited in clinical pharmacology documents.
Q: Are there any age restrictions for using Lucentis?
Lucentis is primarily indicated for treating certain eye conditions in adult patients, generally defined as those 18 years of age or older. However, the official regulatory documents in some regions specify a distinct dose for treating the pediatric condition Retinopathy of Prematurity (ROP) in pre-term infants. No dose adjustment is specified in the official labeling for elderly patients.
Q: Can I continue taking other eye medications during Lucentis treatment?
Official regulatory documents advise against the concurrent use of Lucentis with other anti-VEGF medicines. Aside from this, there are no specific warnings or requirements documented in the drug interaction sections regarding common topical eye drops or other non-Anti-VEGF ocular products.
Q: Is there a risk that Lucentis will not help?
Clinical studies measure the medicine's overall effect based on the average improvements in vision across a large patient group. Official documents acknowledge that individual patient response to treatment may vary. Research is ongoing to examine long-term outcomes and variability in specific patient subgroups, particularly those with other health conditions.
Q: Is there information in official documents about the possibility of using Lucentis for other diseases?
Official regulatory documents, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics, are strictly limited to describing the approved indications. These are the specific diseases for which the medicine has demonstrated sufficient efficacy and safety in required clinical trials. The documentation does not discuss potential use for other conditions.
Q: Is Lucentis use related to the patient's general health?
Yes. Official safety information advises caution for patients with a history of certain systemic conditions. This includes a documented potential for rare systemic events such as arterial thromboembolic events (ATEs), which may include non-fatal stroke and non-fatal myocardial infarction. These warnings are based on the overall safety profile reviewed by regulatory authorities.
Q: Can Lucentis be used to treat both eyes simultaneously?
The medicine is supplied in a single-use vial or pre-filled syringe intended for the treatment of one eye only to maintain sterility. Furthermore, the mandatory minimum interval of four weeks between injections applies specifically to the same eye.
Q: How long does the effect of one Lucentis injection last?
The initial phase of treatment requires consecutive injections approximately every 28 days for a specified number of doses. This frequency is established based on clinical trial data to ensure the medication is renewed at the necessary interval to maintain its therapeutic effect on the growth factor (VEGF-A) being targeted.
Q: Does Lucentis cure the disease or only stop its progression?
Lucentis is indicated for the treatment of specific ocular diseases driven by abnormal blood vessel growth. Its mechanism of action is described as halting the growth and leakage of these abnormal vessels, which serves to prevent disease progression and maintain or improve vision. The official documentation does not describe the medicine as a cure.
Q: Why is it necessary to strictly follow the Lucentis injection schedule?
The required injection schedule is based on clinical trial data demonstrating the precise duration of the therapeutic effect needed to maintain vision gains. Studies indicate that interrupting or significantly deviating from the established schedule can lead to a loss of the visual acuity benefit achieved during treatment.
Q: Is Lucentis approved for use in the European Union or the USA?
Yes. Lucentis (ranibizumab) is approved and licensed for use in the European Union by the European Medicines Agency (EMA) and in the United States by the Food and Drug Administration (FDA). This approval status confirms that the medicine has met the rigorous standards for safety and efficacy in these regions.
Q: If Lucentis treatment is stopped, what will happen to the disease?
The conditions treated by Lucentis, such as wet Age-related Macular Degeneration (AMD), are typically chronic and progressive. Clinical data shows that the therapeutic benefit achieved relies on the medicine being administered continuously or on a defined maintenance schedule. Official documentation indicates that the cessation or reduction of treatment frequency may lead to a loss of visual improvements.
Q: How does Lucentis differ from laser vision correction?
Lucentis is a biologic medicine that works at the molecular level by inhibiting a chemical mediator (VEGF-A) to stop abnormal blood vessel growth. Laser photocoagulation is a distinct procedure that uses focused light energy to treat the retina. The two represent separate therapeutic approaches, sometimes studied in combination to manage the eye condition.
